-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T cells have demonstrated unprecedented efficacy in refractory or relapsed (R/R) multiple myeloma (MM) with overall responses The rate (ORR) is as high as 80%-100%
.
However, some patients relapse, and others do not respond to BCMA CAR T-cell therapy
The combination of BCMA and anti-CD19 chimeric antigen receptor T cells has also been shown to induce high remission rates in patients with relapsed/refractory multiple myeloma, but the long-term effect of this combination is unclear
.
This study is a single-center Phase II clinical trial recruiting patients with relapsed/refractory multiple myeloma who received a combination of anti-BCMA CAR T cells and anti-CD19 CAR T cells after conditioning chemotherapy at a dose of 1x106 cells /kg
.
The primary endpoints were overall response rate, long-term prognosis and safety
Number of patients who responded differently to study treatment
Number of patients who responded differently to study treatmentA total of 69 patients were recruited, 62 of whom received combined anti-BCMA and anti-CD19 CAR T cell infusions with a median follow-up of 21.
3 months
.
The overall response rate was 92% (57/62), with 37 (60%) patients achieving a complete response or better
The overall response rate was 92% (57/62), with 37 (60%) patients achieving a complete response or better The overall response rate was 92% (57/62), and 37 (60%) patients achieved a complete response or better relieve
Progression-free survival and total production period
Progression-free survival and total production periodThe estimated median duration of response was 20.
3 months
.
The median progression-free survival was 18.
The estimated median duration of response was 20.
adverse reactions
adverse reactionsFifty-nine (95%) patients experienced cytokine release syndrome, 10% of which were grade 3 or higher
.
Neurotoxic events occurred in 7 (11%) patients, 3% of which were grade 3 or higher
Taken together, the results of this study show that the combination of anti-B cell maturation antigen and anti-CD19 chimeric antigen receptor T cells induces durable remissions with median progression free in patients with refractory or relapsed multiple myeloma.
Survival was 18.
3 months with a manageable long-term safety profile
.
3 months with a predictable Long-term safety of administration
.
Combination of anti-B-cell maturation antigen and anti-CD19 chimeric antigen receptor T cells induces durable remission in patients with refractory or relapsed multiple myeloma, with a median progression-free survival of 18.
Original source:
Original source:Ying Wang, et al.
leave a message here
